Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX2853 in Advanced Malignancies
NCT03297424Phase 1Completed
- Sponsor
- Opna Bio
- Start
- Sep 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLX2853 in malignant neoplasms (advanced stage), solid tumor, small cell lung cancer (SCLC) and 5 more, sponsored by Opna Bio. Primary endpoints: Number of participants with treatment-related adverse events, Area under the concentration-time curve of PLX2853 and 5 more. Started Sep 2017; status: completed.
02
Drugs
PLX2853
03
Conditions
malignant neoplasms (advanced stage)solid tumorsmall cell lung cancer (SCLC)Uveal melanoma (UM)ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT03297424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297424.